ABCMdb

ABCB1 p.Gly1073Cys

None has been submitted yet.

Publications

PMID: 12226074 [PubMed] Loo TW et al: "The "LSGGQ" motif in each nucleotide-binding domain of human P-glycoprotein is adjacent to the opposing walker A sequence."

No. Sentence Comment

58 The complete cross-linking results between the cysteines in the NBD1 terminal signature sequence (531 LSGGQ535 ) and the cysteines in the NBD2 Walker A site (1070 GSSGCGKS1077 ) are shown in Table I. Residues G1073C and C1074 in the NBD2 Walker A site and L531C and S532C in the NBD1 signature sequence appear to be closest, since mutants L531C/G1073C, L531C/C1074, and S532C/G1073C were cross-linked when treated with oxidant at 4 °C. Login to comment
59 The cysteines in other mutants (e.g. L531C/S1072C, S532/S1072C, and G533C/G1073C) must be further apart, since cross-linked product was only observed at either 21 or 37 °C. Login to comment
66 Representative cross-linking results of two (NBD1 signature/NBD2 Walker A) mutants (L531C/G1073C and L531C/C1074) are shown in Fig. 2. Login to comment
72 The other mutants (Table I) such as L531C/G1073C (Fig. 2) showed no detectable inhibition of cross-linking when preincubated with ATP plus vanadate. Login to comment
74 This appears to be the case for mutants such as L531C/G1073C that showed no inhibition of cross-linking after treatment with ATP plus vanadate. Login to comment
89 CP, copper phenanthroline TABLE I Cross-linking between residues in the NBD1 signature sequence and in the NBD2 Walker A site L531C (21%)a S532C (38%) G533C (91%) G534C (4%) Q535C (0%) 4 °C 21 °C 37 °C 4 °C 21 °C 37 °C 4 °C 21 °C 37 °C 4 °C 21 °C 37 °C 4 °C 21 °C 37 °C G1070C (0%) -b - - - - - - - - - - - - - - S1071C (85%) - - *c - - - - - - - - ϩ - - ϩ S1072C (23%) - ϩc ϩϩd - ϩϩ ϩϩ - - ϩ - - ϩ - - - G1073C (4%) ϩ ϩϩ ϩϩ ϩ ϩϩ ϩϩ - ϩ ϩϩ - - - - - - C1074 (103%) ** ** **d,e - * * - - * - - - - - - G1075C (0%) - - ϩϩ - - ϩ - - - - - - - - - K1076C (12%) - - * - - - - - - - - - - - - S1077C (0%) - - - - - - - - - - - - - - - a Activity of the single cysteine mutant relative to Cys-less P-gp. b No cross-linked product detected in SDS-PAGE. c Relatively weak cross-linking (Ͻ50% of P-gp cross-linked). Login to comment
112 Membranes prepared from HEK 293 cells expressing mutants L531C/ G1073C, L531C/C1074, or L1176C/C431 were preincubated for 10 min at 37 °C in the presence (ϩ) or absence (-) of ATP plus vanadate. Login to comment
131 Hydrolysis of ATP was essential, since inhibition of cross-linking was not observed in the presence of the non-hydrolyzable ATP analog AMP.PNP (data not shown) or in the inactive mutants (e.g. mutant L531C/G1073C; Fig. 2). Login to comment

PMID: 15975613 [PubMed] Brandon EF et al: "Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines."

No. Sentence Comment

56 (2000), was used to determine the *6 (G211A), *7 (T1456G), *27 (C686A), *28 (A(TA)6TAA to A(TA)7TAA), *33 (A(TA)6TAA to A(TA)5TAA), *34 (A(TA)6TAA to A(TA)8TAA) and *29 (C1099G) polymorphisms in the UGT1A1 gene. Login to comment
57 The UGT2B7 polymorphisms A-268G in the promoter region, A386G in exon 1, *2 coding a change of T801A and C802T in exon 2 and G1073C in exon 4 were determined according to the methods described by Bhasker et al. Login to comment
171 W W W W *2 56 normal M H H H G1073C 61 ? Login to comment
169 W W W W *2 56 normal M H H H G1073C 61 ? Login to comment